Crucell Holland B.v.

Mieke Caroline Sprangers

Ronald Vogels

Maria Grazia Pau

Lennart Holterman

Stefan Kostense

Menzo Jans Emco Havenga

Menzo Havenga

Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Settings for recombinant adenoviral-based vaccines

The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Growing community of inventors

Essen, Germany

Mieke Caroline Sprangers